The Loncar Cancer Immunotherapy ETF
About the Fund
The Loncar Cancer Immunotherapy ETF is made up of a basket of companies that develop therapies to
treat cancer by harnessing the body’s own immune system. Immunotherapy is a transformational
field within the biotechnology space that may have a foundational impact on cancer care. By developing
immunotherapies that are more effective and may deliver a better quality of life than currently
available medicines, innovative immunotherapy companies may be making a difference for courageous
patients who battle cancer. Our ETF seeks to support this important work and its positive impact
Cancer immunotherapy has become an important sector in the biotechnology space
Cancer immunotherapy has become an important sector and is changing the way many cancers are treated.
While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using
immunotherapy is derived from the immune system’s dynamic nature and the way it can more precisely
be tailored to fight a patient’s disease. Some immunotherapies have exhibited uncommon results in
clinical trials. Today, many new classes of cancer immunotherapies are being developed. These include
checkpoint inhibitors (which are already FDA approved for types of melanoma, lung, kidney, and bladder
cancer), cancer vaccines, bispecific antibodies, and chimeric antigen receptor (CAR-T) technologies.
With this distinct sector focus, the ETF aims to help investors capture a growth area of the biotechnology
space. At the same time, it will support this method of treating cancer by providing capital to public
companies that are leaders in the space.
Download Investor Materials